Terlipressin plus albumin

Small molecule

Terlipressin plus albumin is one of 15 small molecule programs targeting Hepatorenal Syndrome. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatorenal SyndromeActive, not recruiting

Hepatorenal SyndromePhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Hepatorenal Syndrome

#DrugCompanyPhaseTrials

Glypressin

MMallinckrodt

Approved

12 2

Levophed

GGeneral Hospital of Ningxia Medical University

Phase 3

1 3

Letairis

Gilead

Phase 2

1 4

Proamatine

Takeda

Phase 2

1 5

Noradrenaline

IInstitute of Liver and Biliary Sciences, India

Phase 3

1 6

Giapreza

LLa Jolla Pharmaceutical Company

Phase 2

1 7

NORADRENALIN

UUniversity of Aarhus

Phase 3

1 8

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Phase 2

1 9

Ifetroban

CCumberland Pharmaceuticals

Phase 2

1 10

Sandostatin

Sun Pharma

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatorenal Syndrome2 trials

Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome

Unknown status·UUniversity of Padova·Phase 2/3·NCT00742690·70 enrolled

Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

Terminated·UUniversity of Padova·Phase 2/3·NCT00742339·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Terlipressin plus albumin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Terlipressin plus albumin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Terlipressin plus albumin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Padova company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversity of Padova

Terlipressin plus albumin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatorenal Syndrome2 trials

References

Drug Info

Quick Facts

Related News